Ombitasvir Explained

Iupac Name:	Dimethyl N,N′-biscarbamate
Width:	275
Tradename:	Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir), Technivie (with ombitasvir, paritaprevir, and ritonavir)
Licence Eu:	yes
Legal Us:	Rx-only
Routes Of Administration:	By mouth (tablets)
Bioavailability:	Not determined
Protein Bound:	~99.9%
Metabolism:	Amide hydrolysis followed by oxidation
Onset:	~4 to 5 hours
Elimination Half-Life:	21 to 25 hours
Excretion:	Mostly with feces (90.2%)
Cas Number:	1258226-87-7
Unii:	2302768XJ8
Chebi:	85183
Pubchem:	54767916
Chemspiderid:	31136214
Synonyms:	ABT-267
Kegg:	D10576
C:	50
H:	67
N:	7
O:	8
Smiles:	CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
Stdinchi:	1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
Stdinchikey:	PIDFDZJZLOTZTM-KHVQSSSXSA-N

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1,^{[1] [2]} and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.^{[3] [4]}

Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.^[5]

See also

• Discovery and development of NS5A inhibitors

Further reading

• Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ . 6 . Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials . Open Forum Infectious Diseases . 5 . 11 . ofy248 . November 2018 . 30430131 . 6222025 . 10.1007/s15010-018-1157-x . 1105037362 .
• Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A . 6 . Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study . The Lancet. Gastroenterology & Hepatology . 2 . 6 . 427–434 . June 2017 . 28497758 . 10.1016/S2468-1253(17)30048-1 . 11390/1119739 . free .

Notes and References

1. Web site: VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information. AbbVie Inc., North Chicago, IL 60064. 30 July 2015.
2. Web site: FDA approves Viekira Pak to treat hepatitis C . December 19, 2014 . Food and Drug Administration.
3. Web site: TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information. AbbVie Inc., North Chicago, IL 60064. 28 July 2015. https://web.archive.org/web/20190119043452/https://www.rxabbvie.com/pdf/technivie_pi.pdf. 19 January 2019. dead.
4. Web site: FDA approves Technivie for treatment of chronic hepatitis C genotype 4 . July 24, 2015 . Food and Drug Administration.
5. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B . 6 . Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin . The New England Journal of Medicine . 370 . 17 . 1594–603 . April 2014 . 24720703 . 10.1056/NEJMoa1315722 . amp .